Eighth Study Confirms Health Benefits of CLA in Humans
July 29, 2003, LaGrange, IL— Cognis Nutrition and Health has created a video news release (VNR) being aired on television stations nationwide based on a recent published paper in the Journal of Nutrition (133:257S-260S,2003), showing that Conjugated Linoleic Acid (CLA) may help diabetics manage their blood sugar control and help prevent life-threatening complications. The supplement also proved effective in reducing fat, which also helps control diabetes. This is the eighth article addressing CLA's advantages to be published in a peer-reviewed journal over the last two years.
“Measuring blood glucose levels is one way adults with Type 2 diabetes can monitor their disease, and this study indicates that CLA could be an important link in improving both their body weight and blood glucose levels,” said Martha Belury, Ph.D., lead author of the study and associate professor of human nutrition at The Ohio State University.
In Dr. Belury’s study, fasting blood glucose levels decreased in 81 percent of the subjects (9 of 11) taking CLA supplements, compared with only 20 percent (2 of 10) of those taking placebos. Participants also lost an average of 3.5 pounds during the 8-week study. The study comprised 21 adults with Type 2 diabetes. Eleven participants took 6.8 grams of CLA supplements daily compared to 10 adults who consumed placebos. TONALIN® brand was the CLA used in this study. Subjects enrolled in the study were not taking medication for glucose control, and were instructed to maintain a healthy diet and not to change their diet or activity during the 8-week study.
The researcher found out that higher CLA levels in the blood were associated with lower levels of leptin, a hormone which produces a sense of satiety or feeling full which may ultimately affect appetite. Normal leptin levels may be adversely affected by obesity perhaps indicating why those adults have increased appetites and a slower metabolism. Higher CLA blood levels were also associated with body weight loss.
“Cognis created this Video News Release to further educate health professionals and consumers about the compelling health benefits of CLA,” said Kathleen Moran, Global Market Segment Manager, Dietary Supplements. “Successful marketing tools like this VNR help maintain TONALIN®’s position as the No. 1 selling brand of CLA. We not only invest in the initial science but then reinvest in marketing and press to further support our customers as well as educate consumers at the retail level,” explained Moran.
Additional human studies on health benefits and the body fat reduction aspects of CLA are underway. Recently Cognis announced the first long-term study demonstrating that supplementation with Tonalin® CLA led to a significant reduction in body fat and an increase in lean body mass in healthy overweight adults over the 12-month study. This is the first study to examine CLA’s safety and efficacy long term.
About TONALIN® CLA:
CLA is a polyunsaturated, conjugated fatty acid that is a natural part of the human diet found primarily in meat and dairy products. The CLA content of natural dairy products has fallen over time, and the human body now needs to supplement its consumption of CLA from other sources. TONALIN® CLA is made through a new proprietary process that converts linoleic acid from safflowers into CLA which provides the highest activity available at 80 percent.
For information in North America about TONALIN® brand CLA, please call 800.673.3702 to place an order, e-mail firstname.lastname@example.org, or fax 513.482.3576. For information in Europe, call +49.211.794.9692, e-mail email@example.com, or fax +49.211.798.2390. For information in Asia Pacific, call +61.3.9584.4588, e-mail firstname.lastname@example.org, or fax +61.3.9584.8348.
Cognis (www.cognis.com) is a worldwide supplier of innovative specialty chemicals and nutritional ingredients with almost 9,000 employees in close to 50 countries. The company has dedicated its activities to a high level of sustainability and delivers natural-source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Additionally, Cognis provides solutions for a number of other industries, such as coatings and inks, lubricants, textiles and plastics, as well as agriculture and mining.
Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and Schroder Ventures Life Sciences. In 2002, Cognis recorded sales of 3.1 billion euros and an operating profit before depreciation, amortization and exceptional items (EBITDA recurring) of 393 million euros. A turnover of 748.6 million euros was achieved in the first three months of 2003.
Cognis Nutrition & Health, a business unit of Cognis Group, provides antioxidant (including natural vegetable sterol esters), botanical and nature-based ingredients for dietary supplements; pharmaceuticals and healthcare; functional foods and medical nutrition; and animal nutrition. As a leader in food technology, Cognis manufactures emulsifiers, emulsifier-based compounds, and numerous other specialty products for the food industry worldwide.